As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked. Cambrian BioPharma CEO James Peyer weighs in on the TAME trial.

The new field of longevity science aims to slow aging and make late-life more livable. But will the science ever work? And if so, will it only be for the super rich?

James Peyer, our co-founder and CEO, joins CNBC’s ‘Squawk Box’ to discuss what investors need to know about the growing longevity industry.

Our CEO James Peyer discusses the longevity startup's development of therapeutics to fight age-related diseases. He speaks with Bloomberg's Matt Miller on "Bloomberg Markets."

Cambrian will likely test two of its first three compounds in rare childhood disorders "because the mechanisms work a little bit like fast-aging syndromes," said James Peyer, Ph.D., CEO and co-founder of the biotech.

Cambrian BioPharma Chief Operating Officer, Juliette Han, PhD named as one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report.

"Rational Mind", a science series hosted by engineer and influencer Pietro Boselli, aims to inspire viewers to use rationality and critical thinking to approach complex issues. In this episode, James discusses the longevity science space and the opportunities and challenges ahead.

James Peyer to present new research in the biology of aging at the world's largest Aging Research for Drug Discovery conference.

Does anyone really want to live until 180? Progress in longevity science is abundant at the moment, from healthspan hacking to novel therapies being brought under development. Our panel of experts discuss the philosophical and scientific innovations taking place at the cutting edge of the life-extensionists field and what implications they could have for us all.

Cambrian BioPharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co-founder James Peyer about this new model, why he decided to focus on the biology of aging, and more.

In this session, James Peyer, PhD, CEO of Cambrian BioPharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starting clinical trials with the first geroprotectors.

An exclusive Q&A with Cambrian BioPharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.

A review of recent developments and challenges related to selected blood–brain barrier-crossing strategies — with a focus on non- invasive approaches such as receptor-mediated transcytosis and the use of neurotropic viruses, nanoparticles and exosomes — and analysis of their potential in the treatment of CNS disorders.

James Peyer is the Co-Founder and CEO of Cambrian BioPharma, a Distributed Development Company developing therapeutics targeting the biology of aging. Cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss molecular damage, adding healthy years to your life, prevention vs reversal of diseases, and distributed drug companies.

In 2015, The UN declared February 11th the “International Day of Women and Girls in Science." Today marks the sixth celebration of the vital role women and girls play in science, technology and innovation. We are delighted to showcase some of the women whose work we have covered or will be covering and to play our part in promoting women and girls in science.

Cambrian BioPharma, a new type of biotech venture raising $60 million to execute on a model known as the “Distributed Development Company” or “DisCo,” that is, a multi-asset company combining the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics.

Cambrian BioPharma, a distributed development company, exits stealth mode with the announcement that it has raised $60 million in private financing to develop medicines to extend healthy lifespan.

A study on John Cunningham virus-like particles (JC VLPs) and their potential use in developing a delivery system for transport of genes and small molecule cargoes across the blood-brain barrier (BBB).